Immunovant, Inc.
IMVT
Peringkat dalam Saham
#3098
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase,... Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
Harga Saham
$28.32
Kapitalisasi Pasar
$5.85B
Perubahan (1 hari)
-0.94%
Perubahan (1 tahun)
47.28%
Negara
US
Perdagangan Immunovant, Inc. (IMVT)
Kategori
Healthcare
Riwayat pemecahan saham untuk Immunovant, Inc. (IMVT)
Saham Immunovant, Inc. (simbol: IMVT) telah mengalami total 0 kali pemecahan saham.
Pemecahan saham terbaru terjadi pada Oct 21, 2026.
Satu lembar saham IMVT yang dibeli sebelum Oct 21, 2026 sekarang setara dengan 0 lembar saham IMVT.
Pemecahan saham terbaru terjadi pada Oct 21, 2026.
Satu lembar saham IMVT yang dibeli sebelum Oct 21, 2026 sekarang setara dengan 0 lembar saham IMVT.
Daftar pemecahan saham
| Tahun | Pemecahan | Kelipatan | Kelipatan Kumulatif |
|---|---|---|---|
| Tidak cukup data untuk tanggal yang disediakan. | |||
Pemecahan saham untuk perusahaan sejenis atau pesaing
| Perusahaan | Jumlah pemecahan saham | Kelipatan Kumulatif | Negara |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
NL
|
|
| 0 | - |
CH
|
